drugset / Trial / NCT03589651
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.
Timeline
- Start
- 2018-08-17
- Primary completion
- 2022-11-21
- Completion
- 2022-11-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epacadostat | Small molecule | — | Oral |
| Subject | Parsaclisib | Small molecule | — | Oral |
| Subject | Retifanlimab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.